CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024
July 08 2024 - 8:00AM
CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an
innovative immunotherapy company seeking to advance the next
generation of engineered T cell therapeutics that employ phagocytic
mechanisms, announces presentation of a poster on its lead compound
CER-1236 at the Global Cell & Gene Therapy Summit 2024.
The conference is being held July 8-10 in Boston.
The poster, titled, “Aberrant Expression of TIM-4-L is a Common
Feature of AML and Potential Target for Engineered T Cell Therapy”
presents data showing that TIM-4-L is prevalent on multiple acute
myeloid leukemia (AML) subsets, but not present in healthy
tissue. The study continues that CER-1236, CERo’s lead
compound, showed potent in vitro and in vivo cytotoxicity against
TP53 mutant AML. Further, a full-scale toxicity study
revealed that CER-1236 T cells engraft in lymphoid tissues, but do
not cause any in-life observations, clinical pathology, or
histopathological evaluations. This indicates that CER-1236
is not associated with any adverse toxicities against healthy
tissue, even at high doses. The poster, which is being
presented on July 8, 2024, can be accessed here.
CERo Chairman and CEO Brian G. Atwood comments, “This poster is
validation of our recent announcement regarding the completion of
toxicity evaluations for CER-1236. The prevalence of TIM-4-L
in AML as compared to healthy tissue is important, as it makes it a
viable target that may have an impact on the disease.
CER-1236 action in AML compared to in healthy tissue also shows
promise for the compound. Cell & Gene Therapy is an
important conference, and the acknowledgement of these data will be
instrumental in further discussion with the scientific community in
explaining the potential we see for our compound.
“In the meantime, with all IND-enabling work complete, we are in
close communication with the U.S. Food and Drug Administration as
we prepare for the possibility of entering the clinic with CER-1236
for AML in the short term,” concluded Mr. Atwood.
About CERo Therapeutics, Inc.CERo is an
innovative immunotherapy company advancing the development of next
generation engineered T cell therapeutics for the treatment of
cancer. Its proprietary approach to T cell engineering, which
enables it to integrate certain desirable characteristics of both
innate and adaptive immunity into a single therapeutic construct,
is designed to engage the body’s full immune repertoire to achieve
optimized cancer therapy. This novel cellular immunotherapy
platform is expected to redirect patient-derived T cells to
eliminate tumors by building in engulfment pathways that employ
phagocytic mechanisms to destroy cancer cells, creating what CERo
refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo
believes the differentiated activity of CER-T cells will afford
them greater therapeutic application than currently approved
chimeric antigen receptor (“CAR-T”) cell therapy, as the use of
CER-T may potentially span both hematological malignancies and
solid tumors. CERo anticipates initiating clinical trials for its
lead product candidate, CER-1236, in 2024 for hematological
malignancies.
Forward-Looking StatementsThis communication
contains statements that are forward-looking and as such are not
historical facts. This includes, without limitation, statements
regarding the financial position, business strategy and the plans
and objectives of management for future operations of CERo. These
statements constitute projections, forecasts and forward-looking
statements, and are not guarantees of performance. Such statements
can be identified by the fact that they do not relate strictly to
historical or current facts. When used in this communication, words
such as “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “might,” “plan,” “possible,”
“potential,” “predict,” “project,” “should,” “strive,” “would” and
similar expressions may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. When CERo discusses its strategies or plans, it is
making projections, forecasts or forward-looking statements. Such
statements are based on the beliefs of, as well as assumptions made
by and information currently available to, CERo’s management.
Actual results could differ from those implied by the
forward-looking statements in this communication. Certain risks
that could cause actual results to differ are set forth in CERo’s
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K, filed on April 2, 2024, and the
documents incorporated by reference therein. The risks described in
CERo’s filings with the Securities and Exchange Commission are not
exhaustive. New risk factors emerge from time to time, and it is
not possible to predict all such risk factors, nor can CERo assess
the impact of all such risk factors on its business, or the extent
to which any factor or combination of factors may cause actual
results to differ materially from those contained in any
forward-looking statements. Forward-looking statements are not
guarantees of performance. You should not put undue reliance on
these statements, which speak only as of the date hereof. All
forward-looking statements made by CERo or persons acting on its
behalf are expressly qualified in their entirety by the foregoing
cautionary statements. CERo undertakes no obligation to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by law.
Contact: Brian Atwood Chief Executive Officer
batwood@cero.bio
Investors:CORE IRinvestors@cero.bio
CERo Therapeutics (NASDAQ:CERO)
Historical Stock Chart
From Oct 2024 to Nov 2024
CERo Therapeutics (NASDAQ:CERO)
Historical Stock Chart
From Nov 2023 to Nov 2024